NCT03451370 2026-04-15
COBRA
Istituto Oncologico Veneto IRCCS
Active not recruiting
Clinical Trials
27 trialsNCT02394834 2026-04-13
An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer
Takeda
Active not recruiting
NCT06718257 2025-02-06
Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Recruiting
NCT04679597 2024-10-17
Total Neoadjuvant Therapy Versus Standard Therapy of Locally Advanced Rectal Cancer With High Risk Factors for Failure
Institute of Oncology Ljubljana
Completed
NCT06504875 2024-07-17
Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Not yet recruiting
NCT06504901 2024-07-17
Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases
The First Affiliated Hospital with Nanjing Medical University
Not yet recruiting
NCT06194981 2024-01-12
Duration of Adjuvant Chemotherapy for Gastric Cancer Patients at Pathological N3 Stage
The First Affiliated Hospital of Zhengzhou University
Unknown
NCT06196554 2024-01-09
Gastric Cancer Organoids in the Screening of Neoadjuvant Drugs
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Unknown
NCT06068023 2023-10-05
ADAPTA
Fondazione Poliambulanza Istituto Ospedaliero
Recruiting
NCT05176964 2023-09-25
Chemotherapy and Tislelizumab With Split-course HFRT for Locally Advanced Rectal Cancer
Fujian Medical University Union Hospital
Unknown
NCT05489692 2022-08-10
HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma
Sun Yat-sen University
Completed
NCT03001726 2022-05-06
To Observe the Efficacy and Safety by Comparing Chemotherapy(Docetaxel, Oxaliplatin Plus S1 ) Followed With Radical Resection Versus Chemotherapy Alone in Advanced Gastric Cancer With Single Non-curable Factor.
Shanghai Zhongshan Hospital
Unknown
NCT02860234 2021-07-23
Tailored Operative or Non-operative Management for Low-risk Rectal Cancer After Intensive Neoadjuvant Treatment
Peking University Cancer Hospital & Institute
Completed
NCT04913896 2021-06-04
CT and MRI in Prediction of Response in Patients With Gastric Cancer Following Neoadjuvant Chemotherapy and/or Immunotherapy
The First Hospital of Jilin University
Unknown
NCT02135887 2020-12-22
MB-6
Microbio Co Ltd
Unknown
NCT04405206 2020-10-14
BJCC-R01
Peking University Cancer Hospital & Institute
Unknown
NCT02970526 2020-09-16
PREVOX
University Hospital, Clermont-Ferrand
Completed
NCT04122885 2019-10-10
IMMUNOPAC
University Hospital Tuebingen
Unknown
NCT03923036 2019-04-22
AVOCETTE
University Hospital, Caen
Unknown
NCT03668418 2018-09-12
xenoZ
University of Pisa
Unknown
NCT03532711 2018-05-22
Potential Predictive Biomarkers in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer
Fudan University
Completed
NCT03237507 2017-08-02
Nonintervention Study on Peritoneal Metastasis of Stage IV Gastric Cancer
Harbin Medical University
Unknown
NCT03034850 2017-01-27
Thrombin Generation and Platelet Activation in CRS/HIPEC
Ziekenhuis Oost-Limburg
Completed
NCT01399190 2016-09-28
An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer
Hoffmann-La Roche
Completed
NCT02412683 2016-09-07
Neurotoxic Symptoms in Adjuvant Chemotherapy in Patients With Colorectal Cancer
Linkoeping University
Completed
NCT01442155 2016-07-07
An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer
Hoffmann-La Roche
Completed
NCT01311050 2011-12-13
A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer
King Faisal Specialist Hospital & Research Center
Unknown